This clinical trial is focused on studying a type of lung cancer known as Metastatic Non-small Cell Lung Cancer (NSCLC). This is a condition where cancer cells from the lungs have spread to other parts of the body. The study is testing a combination of two treatments: Amivantamab and Cetrelimab. These treatments are given as a solution through a vein, which is known as an infusion. The purpose of the study is to find the best dose of these treatments and to see how well they work together in fighting this type of lung cancer.

Participants in the study will receive the combination of Amivantamab and Cetrelimab. The study will be conducted in two phases. In the first phase, researchers will determine the most suitable dose of the combination treatment. In the second phase, they will evaluate how effective the treatment is in reducing the size of the cancer or stopping its growth. The study will also look at the safety of the treatment and any side effects that may occur.

This trial is designed to help understand how the combination of these two treatments can benefit people with NSCLC, especially those whose cancer has specific characteristics related to EGFR and PD-L1 status. The study aims to provide valuable information that could lead to better treatment options for patients with this type of lung cancer.